The Chamber of Commerce urged a federal judge on Friday to stop the new Medicare drug price negotiation program before Oct. 1 ...

Drug companies challenging the law in court could still have several chances to stop the program before next year's election.

Boehringer Ingelheim is the latest large drugmaker to challenge the U.S. government over Medicare’s new power to negotiate prices of select top-selling medicines, filing a 62-page lawsuit Friday ...

The Southern District Court of Ohio on Friday heard oral arguments from the federal government and the Chamber of Commerce in ...

One Republican mocked Medicare drug price negotiation as “godfather mafia-style” policy, saying it lets the government steal ...

“Congress knew that withdrawing all products from federal healthcare programs would be economic suicide—not a ‘real option.’” – U.S. Chamber motion for preliminary injunction On August ...

Aug 31 (Reuters) - Drugmakers challenging a Biden administration program requiring them to negotiate with Medicare over the prices of selected costly drugs may not have a clear legal precedent on ...

The Biden administration has picked the first 10 high-priced prescription drugs subject to federal price negotiations, taking a swipe at the powerful pharmaceutical industry. It marks a major ...

The legal challenges to President Biden's drug price negotiation law could be on a collision course with the 2024 election. Why it matters: Should the Medicare negotiation program survive its first ...

Boehringer Ingelheim has become the latest drugmaker to sue the US government over the Medicare drug price negotiation element of President Biden's signature Inflation Reduction Act (IRA). The IRA ...

Another diabetes drug maker is taking legal action against businesses in several states, alleging that they're "fraudulently ...

A major turning point in the battle to control ever-rising drug prices The Biden administration has picked the first 10 high-priced prescription drugs subject to federal price negotiations, taking ...